SCHEMBL23629015

SCHEMBL23629015

CCn1c(C)c(Cl)c(Cl)c1C(=O)Nc1nc2ccc(C(=O)OCc3ccc(OC)cc3)cc2s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.53
RAB9A P51151 9/20 0.53
SCD O00767 8/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
SMN1; SMN2 Q16637 7/20 0.51
KDM4E B2RXH2 5/20 0.51
MAPT P10636 2/20 0.51
ALDH1A1 P00352 3/20 0.49
TP53 P04637 2/20 0.49
HSD17B10 Q99714 2/20 0.49
USP2 O75604 1/20 0.49
STAT1 P42224 1/20 0.49
CSNK1D P48730 3/20 0.49
HPGD P15428 2/20 0.48
GSK3B P49841 1/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23628906 0.88 SCD (0.52) NPC1RAB9ASCDMEN1KMT2A
SCHEMBL23628931 0.87 SCD (0.51) NPC1RAB9ASCDMEN1KMT2A
SCHEMBL23629022 0.82 HSD17B10 (0.56) NPC1RAB9ASCDMEN1KMT2A
SCHEMBL23628984 0.79 SCD (0.60) NPC1RAB9ASCDMEN1KMT2A
SCHEMBL23629019 0.78 GSK3B (0.55) NPC1RAB9ASCDMEN1KMT2A
SCHEMBL23628959 0.76 GSK3B (0.54) NPC1RAB9ASCDMEN1KMT2A
SCHEMBL23628889 0.74 HSD17B10 (0.53) NPC1RAB9ASCDSMN1; SMN2KDM4E
SCHEMBL23629027 0.74 GSK3B (0.52) NPC1RAB9ASCDMEN1KMT2A
SCHEMBL4932123 0.74 SCD (0.82) NPC1RAB9ASCDMEN1KMT2A
SCHEMBL23628930 0.73 MAPT (0.55) NPC1RAB9ASCDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258342-B2 Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria UNIVERZA V LJUBLJANI (SI) 2025-03-25 US disclosed
US-20210323957-A1 NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA UNIVERZA V LJUBLJANI (SI) 2021-10-21 US disclosed
EP-3847172-A1 NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA Univerza v Ljubljani (SI) 2021-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323957-A1 NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA TOP1, TOP2A, TOP2B NPC1 4573/4885RAB9A 3897/4885SCD 3587/4885
US-12258342-B2 Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria TOP1, TOP2A, TOP2B NPC1 4546/4885RAB9A 3924/4885SCD 3373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.